Jul 18, 2022 | Comment Letters
The Centers for Medicare and Medicaid (CMS) recently held a comment period as they reconsidered limitations on scans to detect Dementia. The current system only allows for a single PET scan to be covered by CMS for an Alzheimer’s patient enrolled in a clinical...
Read more
Apr 9, 2022 | Access, Featured
On this episode of the podcast, Terry and Bob discuss the access and affordability challenges that patients with Alzheimer’s and diabetes face. They highlight a new analysis that concludes an enormous $350 billion of prescription drug rebates were spent last...
Read more
Apr 9, 2022 | Access, Featured
WASHINGTON — Patients Rising Now Executive Director Terry Wilcox today released the following statement in response to CMS’ final decision to restrict access to FDA-approved Alzheimer’s treatments to clinical trial participants: “It’s a sad day for the millions...
Read more
Jan 14, 2022 | Public Statement
Proposed decision will Exacerbate Health Inequities, Undermine FDA WASHINGTON — Patients Rising Executive Director Terry Wilcox today released the following statement regarding the Centers for Medicare and Medicaid Service proposed decision on the national coverage...
Read more
Jul 27, 2021 | Featured, Podcast
On this episode of the podcast, Terry and Bob discuss the growing barriers to access prescription drugs and the ongoing drug price debate spurred by the recent approval of a new Alzheimer’s drug. Terry discusses ICER’s recent conclusion that the...
Read more
